Skip to main content
logo
Xenon Pharmaceuticals Inc. (XENE)
NASDAQ: XENE · Real-Time Price · USD
60.56
-0.21 (-0.35%)
Aug 24, 2026, 4:00 PM EDT - Market closed

Xenon Pharmaceuticals Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
-7.5--9.4318.44
Revenue Growth
-----48.83%-42.68%
Cost of Revenue
352.49300.94210.39167.51105.7775.46
Gross Profit
-352.49-293.44-210.39-167.51-96.33-57.03
Selling, General & Admin
89.179.6368.946.5432.8121.97
Operating Expenses
89.179.6368.946.5432.8121.97
Operating Income
-441.59-373.07-279.3-214.05-129.14-78.99
Interest & Investment Income
30.626.8341.9427.628.710.47
Currency Exchange Gain (Loss)
-0.151.35-1.060.2-1.890.36
EBT Excluding Unusual Items
-411.14-344.89-238.42-186.24-122.32-78.17
Gain (Loss) on Sale of Investments
---3.55-2.93-0.72
Pretax Income
-411.14-344.89-238.42-182.69-125.26-78.89
Income Tax Expense
-1.941.02-4.09-0.290.12-0.01
Net Income
-409.2-345.91-234.33-182.39-125.37-78.88
Preferred Dividends & Other Adjustments
------1.8
Net Income to Common
-409.2-345.91-234.33-182.39-125.37-77.09
Net Income Growth
------
Shares Outstanding (Basic)
877978676144
Shares Outstanding (Diluted)
877978676144
Shares Change
10.31%1.75%16.45%10.48%38.77%21.09%
EPS (Basic)
-4.73-4.36-3.01-2.73-2.07-1.77
EPS (Diluted)
-4.73-4.36-3.01-2.73-2.07-1.77
EPS Growth
------

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-338.53-279.92-184.46-156.73-103.92-71.55
Free Cash Flow Per Share
-3.91-3.53-2.37-2.34-1.72-1.64
Operating Margin
--4974.27%---1368.91%-428.45%
Profit Margin
--4612.13%---1328.95%-418.11%
Free Cash Flow Margin
--3732.23%---1101.57%-388.09%
EBITDA
-439.19-370.53-276.74-211.99-127.74-78.09
D&A For EBITDA
2.42.542.562.061.410.91
EBIT
-441.59-373.07-279.3-214.05-129.14-78.99
SEC Filings: 10-K · 10-Q